Summary (from the latest annual and quarterly report)

• Total equity: 18.14 billion USD
• Market Cap is 88.9 billion USD ( the last price of the stock is 69 USD)
• Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally
• Total stockholders' equity has decreased from 22.65 billion USD in 2019 to 18.14 billion in 2020
• The company has 11 billion USD in cash on account
• Total equity – cash on account = 18.14 billion USD – 11 billion USD = 7.14 billion USD
• In Jun 2020 long-term debt was 27.22 billion USD, short – term debt was zero. (In 2019 total debt was 25 billion USD)
• The company's revenue has increased in 2019 to 22.4 billion USD from 22.12 billion in 2018
• Net income in 2019 was 5.38 billion USD, Net income in 2018 was 5.45 billion USD
• In 2019 the company has paid 3.22 billion USD dividend to its shareholders

Opinion about the company

Fundamentally it is a good company and in the future, we can expect its growth (Total debt is 27.22 billion USD, big amount of cash on the company's account, ROE is around 22 %).

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners.

 GILD standalone subsidiaries and acquisitions :

• In March 1999, Gilead acquired NeXstar Pharmaceuticals for 550 million USD
• In 2003, Gilead acquired Triangle Pharmaceuticals for 464 million USD (Triangle owned the development and commercialization rights to emtricitabine, which although marketed as a stand-alone product (Emtriva), is also a component of the more profitable combination products Atripla and Truvada)
• In 2006, Gilead acquired Corus Pharma for 365 million USD (The acquisition of Corus signaled Gilead's entry into the respiratory arena. Corus was developing aztreonam lysine for the treatment of patients with cystic fibrosis who are infected with Pseudomonas aeruginosa)
• In 2006, Gilead acquired Myogen for 2.5 billion USD, the acquisition of Myogen has solidified Gilead's position in this therapeutic arena
• In 2006, Gilead acquired Raylo Chemicals for 148 million USD
• In 2007, Gilead acquired Nycomed fr. Altana - Cork for 47 million USD
• In 2009, Gilead acquired CV Therapeutics for 1.4 billion USD (this acquisition brings Ranexa and Lexiscan as commercial products. Ranexa is a cardiovascular drug used to treat chest pain related to coronary artery disease. These products and pipeline build out Gilead's cardiovascular franchise)
• In 2010, Gilead acquired CGI Pharmaceuticals for 120 million USD
• In 2010, Gilead acquired Arresto Biosciences for 225 million USD
• In 2011, Gilead acquired Calistoga Pharmaceuticals for 375 million USD
• In 2011, Gilead acquired Pharmasset for 10.4 billion USD,  this acquisition helps Gilead take the lead in HCV with 7977 (Sofosbuvir)
• In 2013, Gilead acquired YM Biosciences for 510 million USD
• In 2015, Gilead acquired Phenex Pharmaceuticals for 470 million USD
• In 2015, Gilead acquired EpiTherapeutics for 65 million USD
• In 2015, Gilead paid 425 million USD for a 15% equity stake in Galapagos NV, with additional payments for Gilead to license the experimental anti-inflammatory drug filgotinib, which may treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease
• In 2016, Gilead acquired Nimbus Apollo for 400 million USD, this acquisition will give Gilead the compound NDI-010976 (an ACC inhibitor) and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis and for the potential treatment of hepatocellular carcinoma
• In August 2017, the company announced it would acquire Kite Pharma for 11.9 billion USD, equating to $180 cash per share, a 29% premium over the closing price of the shares. The deal will add the promising CAR-T candidate to the companys existing portfolio. In November, the company announced it will acquire Cell Design Labs for up to 567 million USD, after it indirectly acquired a stake of 12.2% via the Kite Pharma deal
• In March 2020, the company announced it would acquire Forty Seven Inc. for $95.50 a share (4.9 billion USD in total). On April 7, 2020, Gilead completed the acquisition of Forty Seven, Inc. for "$95.50 per share, net to the seller in cash, without interest, or approximately 4.9 billion in the aggregate

Total = 35.8 billion usd

• In June 2020, Bloomberg reported that AstraZeneca Plc had made a preliminary approach to Gilead for a potential merger, worth almost $240 billion. In the same month, the company announced it would acquire a 49.9% stake in privately held Pionyr Immunotherapeutics Inc for $275 million
• On May 9, 2019, the U.S. Department of Health and Human Services announced that Gilead Sciences will donate Truvada, the only drug approved to prevent infection with H.I.V., for free to 200,000 patients annually for 11 years. On December 3, 2019, HHS explained how the government would distribute the donated drugs. HHS Secretary Alex Azar explained that the U.S. government will pay Gilead $200 per bottle for 30 pills for costs associated with getting the drug from factories into the eventual hands of patients